Myeloma Canada is pleased to share that on April 13, 2023 Sarclisa (isatuximab) was granted exceptional drug status and is now reimbursed by Quebec under the public drug program for its use in hospitals! Quebec is the first Canadian province to officially reimburse this drug.

As of May 1st, 2023 Alberta joined Quebec in approving the reimbursement of isatuximab!

The following drug combinations were added to the list of drugs reimbursed by the provinces: 

• Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone
• Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone 

See complete list of drugs reimbursed in Quebec (in French)

See complete list of drugs reimbursed in Alberta (in English)